#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Cannabinoid hyperemesis syndrome (CHS) represents an emerging clinical entity that clinicians must recognize given the rising prevalence of cannabis use, particularly high-potency products, which increases the likelihood of encountering this paradoxical condition in practice. Early identification of CHS is critical because patients often undergo extensive gastrointestinal workup and unnecessary interventions before diagnosis, while the definitive treatment—cannabis cessation—remains underutilized without clinical awareness. Understanding the constellation of symptoms associated with CHS improves diagnostic accuracy and reduces morbidity in a population with expanding cannabis access.
Cannabis hyperemesis syndrome is an increasingly recognized clinical entity affecting chronic heavy cannabis users, characterized by cyclical episodes of severe nausea, vomiting, and abdominal pain that paradoxically respond to hot water immersion or bathing. The rising incidence of CHS presentations reflects both increased cannabis potency and consumption patterns, particularly with the availability of high-THC products and concentrates in legalized markets. Clinicians should maintain a high index of suspicion for CHS in patients presenting with recurrent unexplained nausea and vomiting, especially those reporting heavy daily cannabis use and atypical responses to standard antiemetic therapy. The diagnosis is primarily clinical and based on symptom pattern and cannabis exposure history, as no specific biomarkers currently exist. Understanding CHS pathophysiology and presentation is essential for avoiding unnecessary diagnostic workup and inappropriate treatments in this growing patient population. Physicians should counsel heavy cannabis users about CHS risk and consider cannabis cessation as the definitive therapeutic intervention, while recognizing that patient education regarding this syndrome may improve early identification and appropriate management.
“Cannabis hyperemesis syndrome represents a real and increasingly common clinical presentation that we’re seeing in heavy, frequent users, particularly those consuming high-potency products, and it demands we take seriously the difference between cannabis use and cannabis abuse in our patient populations.”
Cannabinoid hyperemesis syndrome (CHS) represents an increasingly recognized clinical entity characterized by cyclical nausea, vomiting, and abdominal pain in chronic cannabis users, with symptoms often paradoxically improving with hot showers. The syndrome’s pathophysiology remains incompletely understood, though theories suggest dysregulation of cannabinoid receptors in the central nervous system and altered thermoregulation contribute to symptom manifestation. Recognition of CHS is clinically important as affected patients frequently undergo extensive diagnostic workups and interventions before cannabis cessation is identified as definitive treatment. The rising prevalence of CHS correlates with increased cannabis potency and frequency of use in recent years, making clinician awareness and patient education essential components of comprehensive care. Early identification based on characteristic symptom patterns and detailed substance use history can prevent unnecessary investigations and facilitate appropriate management.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: